Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about REGN
Recent news which mentions REGN
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
January 16, 2025
Tickers
NEWS
REGN
Tags
Trading Ideas
News
BZI/POD
From
Benzinga
Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
January 14, 2025
Tickers
NEWS
REGN
Tags
General
News
Market News
From
Benzinga
Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
January 10, 2025
Tickers
REGN
Tags
BZI/AAR
Market News
Benzinga
From
Benzinga
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
January 09, 2025
Tickers
AMGN
BMY
GILD
LLY
Tags
MRK
Briefs
REGN
From
Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
January 08, 2025
Tickers
REGN
Tags
Analyst Ratings
REGN
Benzinga
From
Benzinga
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
January 02, 2025
Tickers
REGN
Tags
REGN
Market News
Recent Press Releases
From
Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
December 23, 2024
Tickers
NEWS
REGN
Tags
Trading Ideas
News
BZI/POD
From
Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
Tickers
ABBV
BMY
ELAN
GILD
Tags
Large Cap
Biotech
VTRS
From
Benzinga
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
December 17, 2024
Tickers
BAYRY
NEWS
REGN
Tags
News
Top Stories
BAYRY
From
Benzinga
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
December 17, 2024
Tickers
APA
ASML
AVGO
CEG
Tags
Broad U/S/ Equity ETFs
MRVL
NVDA
From
Benzinga
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
December 17, 2024
Tickers
REGN
Tags
BZI/AAR
Market News
Benzinga
From
Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
December 04, 2024
Tickers
LB
LLY
NEWS
NVTS
Tags
SNY
Media
Market News
From
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 26, 2024
Tickers
REGN
Tags
Markets
BZI/UOA
Options
From
Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
November 19, 2024
Tickers
REGN
Tags
REGN
Benzinga
Market News
From
Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
November 18, 2024
Tickers
REGN
Tags
Short Ideas
Trading Ideas
REGN
From
Benzinga
Check Out What Whales Are Doing With REGN
November 15, 2024
Tickers
REGN
Tags
Benzinga
Options
Market News
From
Benzinga
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
November 15, 2024
Tickers
NEWS
REGN
SNY
Tags
General
News
Top Stories
From
Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
November 14, 2024
Tickers
REGN
Tags
Benzinga
Market News
REGN
From
Benzinga
2 Top Growth Stocks to Buy on the Dip
November 14, 2024
Tickers
LLY
REGN
Tags
Market News
Recent Press Releases
LLY
From
Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
Tickers
AZN
GSK
NEWS
REGN
Tags
SNY
Health Care
Market News
From
Benzinga
Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
November 06, 2024
Tickers
NEWS
REGN
Tags
News
Market News
Markets
From
Benzinga
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
November 06, 2024
Tickers
ASML
DELL
IDXX
MRNA
Tags
MRNA
ASML
Market News
From
Motley Fool
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Tickers
AMGN
AZN
NEWS
REGN
Tags
General
News
Top Stories
From
Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
November 04, 2024
Tickers
REGN
Tags
Market News
Options
Benzinga
From
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
October 31, 2024
Tickers
NEWS
NVO
REGN
SNY
Tags
News
General
NVO
From
Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
Tickers
AAPL
AMGN
AMZN
BKNG
Tags
MSTR
BMY
ETN
From
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Tickers
ABBV
AMGN
BIIB
BMY
Tags
ABBV
News
General
From
Benzinga
EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
October 28, 2024
Tickers
EYPT
NEWS
REGN
Tags
Movers
Health Care
Market News
From
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
Tickers
AMGN
CMG
GS
LLY
Tags
ROG
NVDA
Recent Press Releases
From
Motley Fool
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
October 25, 2024
Tickers
LLY
NEWS
REGN
SNY
Tags
SNY
Market News
Equities
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.